Sanofi Fundamental Analysis (XETRA: SNW.DE)
Sanofi (XETRA: SNW.DE) shows moderate financial fundamentals with a PE ratio of 24.08, profit margin of 11.18%, and ROE of 9.43%. The company generates $60.7B in annual revenue with moderate year-over-year growth of 5.49%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 59.8/100 based on profitability, valuation, growth, and balance sheet metrics. The C grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze SNW.DE's fundamental strength across five key dimensions:
Efficiency Score
WeakSNW.DE struggles to generate sufficient returns from assets.
Valuation Score
ExcellentSNW.DE trades at attractive valuation levels.
Growth Score
ExcellentSNW.DE delivers strong and consistent growth momentum.
Financial Health Score
ModerateSNW.DE shows balanced financial health with some risks.
Profitability Score
WeakSNW.DE struggles to sustain strong margins.
Key Financial Metrics
Is SNW.DE Expensive or Cheap?
P/E Ratio
SNW.DE trades at 24.08 times earnings. This indicates a fair valuation.
PEG Ratio
When adjusting for growth, SNW.DE's PEG of -0.38 indicates potential undervaluation.
Price to Book
The market values Sanofi at 1.36 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 7.83 times EBITDA. This is generally considered low.
How Well Does SNW.DE Make Money?
Net Profit Margin
For every $100 in sales, Sanofi keeps $11.18 as profit after all expenses.
Operating Margin
Core operations generate 25.94 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $9.43 in profit for every $100 of shareholder equity.
ROA
Sanofi generates $5.24 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Sanofi generates strong operating cash flow of $17.54B, reflecting robust business health.
Free Cash Flow
Sanofi generates strong free cash flow of $14.48B, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $12.06 in free cash annually.
FCF Yield
SNW.DE converts 15.26% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
24.08
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-0.38
vs 25 benchmark
P/B Ratio
Price to book value ratio
1.36
vs 25 benchmark
P/S Ratio
Price to sales ratio
1.56
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.34
vs 25 benchmark
Current Ratio
Current assets to current liabilities
0.99
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.09
vs 25 benchmark
ROA
Return on assets percentage
0.05
vs 25 benchmark
ROCE
Return on capital employed
0.16
vs 25 benchmark
How SNW.DE Stacks Against Its Sector Peers
| Metric | SNW.DE Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 24.08 | 32.14 | Better (Cheaper) |
| ROE | 9.43% | 550.00% | Weak |
| Net Margin | 11.18% | 30133.00% | Weak |
| Debt/Equity | 0.34 | 0.56 | Strong (Low Leverage) |
| Current Ratio | 0.99 | 5.70 | Weak Liquidity |
| ROA | 5.24% | 3.00% | Excellent |
SNW.DE outperforms its industry in 3 out of 6 key metrics, particularly excelling in ROA, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Sanofi's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
28.41%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
-34.72%
Industry Style: Defensive, Growth, Innovation
DecliningFCF CAGR
48.24%
Industry Style: Defensive, Growth, Innovation
High Growth